Relmada Therapeutics Inc. (NASDAQ: RLMD) is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for the treatment of central nervous system (CNS) diseases, particularly those related to pain management. With its significant portfolio, the company is poised to address several substantial unmet medical needs in the global therapeutic market.
Founded in 2004 and headquartered in New York, Relmada Therapeutics is dedicated to delivering life-changing solutions to patients suffering from CNS disorders. The company combines cutting-edge science and clinically validated methodologies to advance the development of its pioneering CNS therapeutical offerings.
The flagship candidate of Relmada's product portfolio is REL-1017, a N-methyl-D-aspartate (NMDA) receptor antagonist, currently in Phase 3 clinical trials as a treatment for major depressive disorder (MDD). REL-1017 works by modulating the glutamatergic system, which holds significant potential for treating various mood and cognitive disorders. This investigational drug has been given Fast Track designation by the U.S. Food and Drug Administration (FDA), indicating the urgency of developing a drug for this severe and life-threatening condition. If approved, it could provide substantial improvements over existing therapies.
Relmada Therapeutics has a unique platform for progressing medicines from novel drug discovery through to late-stage clinical development. Fueled by a devoted team of distinguished specialists and a proficient and seasoned management squad that collectively has extensive experience in drug development and commercialization, the company is well-equipped to take on the various challenges of CNS drug production.
The company's strategic endeavors are also financed robustly, an aspect that enhances its flexibility and capability to deliver its business objectives on time. As part of its financial strategy, Relmada accomplished a $115 million public offering in June 2020, which has strengthened the company’s balance sheet and will facilitate the continued development of its pipeline candidates.
Relmada Therapeutics is paving the way in CNS disorders. With the substantial progress the company is making in the clinical development of REL-1017, it is on track to potentially deliver a significant new treatment option for MDD. Above all, Relmada Therapeutics remains committed to sourcing, developing, and commercializing novel therapeutics that could improve the lives of patients battling CNS conditions around the world.